Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...
The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal ...
(RTTNews) - REGENXBIO Inc. (RGNX) announced the FDA has granted Fast Track designation for RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy. RGX-202 has been ...
Teva Pharmaceuticals (NYSE:TEVA) said that the U.S. FDA has granted fast track designation to its experimental therapy TEV-56286 (emrusolmin) for treating Multiple System Atrophy. Emrusolmin, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback